Isodiol International Inc. Announces KURE Corp Expansion Plans

Biotech Investing
Biotech Investing

Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global CBD innovator specializing in the development of pharmaceutical and health and wellness products and now supporting the pharmaceutical industry at large with its recently approved CBD as an Active Pharmaceutical Ingredient, announces that its wholly owned subsidiary, KURE Corp (“KURE”), has finalized plans for the expansion of its national retail footprint.

Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global CBD innovator specializing in the development of pharmaceutical and health and wellness products and now supporting the pharmaceutical industry at large with its recently approved CBD as an Active Pharmaceutical Ingredient, announces that its wholly owned subsidiary, KURE Corp (“KURE”), has finalized plans for the expansion of its national retail footprint. KURE plans to expand by opening several brick and mortar locations, acquiring existing vapor stores and introducing their new KURE Vape Pod™ concept in cities across the US and Canada.

KURE has signed a representation agreement with Newmark Knight Frank (NKF), one of the world’s leading commercial real estate advisory firms.  Newmark Knight Frank  is operated by the Newmark Group, Inc. (NASDAQ: NMRK).

Under the agreement, the Newmark Group has identified several national real estate investment trusts (REIT’s) who will provide Class A retail locations for the KURE Vape Pod™. The initial roll-out plan is for 10 cities across the United States with additional cities to be announced.

SG Blocks, Inc. (Nasdaq: SGBX), a leading designer, innovator and fabricator of container-based structures have teamed up to create an extraordinarily unique experience for the vaping industry.  Introducing, the KURE Vape Pod™, a sleek vaporium within a 20’ x 24’ shipping containers structure, allowing for the same quality customer experience you receive in a stationary KURE store, but within a smaller and eco-friendly footprint.

It is estimated that the initial 10 locations will be a total cap ex cost of $2 million.  The current 12 KURE stores average $900,000 USD per location in annual gross sales. KURE will also be adding Isodiol’s CBD products, including a new kathy ireland Health & Wellness product line in Q2 2018.

“KURE has established itself as a leading specialty vape retailer and this expansion further reflects the demand KURE has been receiving from customers,” said CEO of Isodiol, Marcos Agramont. “With our newly formed partnership, KURE is now able to provide consumers with a variety of innovative CBD products. We will also continue to focus on our plans for further domestic and international expansion.”

KURE CEO Craig Brewer said, “We pride ourselves in offering an exceptional experience that is personalized for every customer through our modern and sophisticated retail environment and lounge with unparalleled customer service. With the merger of Isodiol we are now able to offer our customers an even more extensive variety of products.”

“We strive to help our clients grow our their businesses,” said Kathy Ireland, Level Brands Chairman Emeritus and Chief Brand Strategist (NYSE:LEVB). This partnership is a great example of how we maximize our relationships between our brand partners.”

For more information on Isodiol, please visit www.isodiol.com

For more information on KURE Corp, please visit www.kurevapes.com

About Isodiol International Inc.

Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of CBD consumer products.

Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products and most recently received approval as having the first CBD designated as an Active Pharmaceutical Ingredient as was announced April 26, 2018.

Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.

About SG Blocks, Inc.

SG Blocks, Inc. is a premier innovator in advancing and promoting the use of code- engineered cargo shipping containers for safe and sustainable construction. The firm offers a product that exceeds many standard building code requirements, and also supports developers, architects, builders and owners in achieving greener construction, faster execution, and stronger buildings of higher value. Each project starts with GreenSteel™, the structural core and shell of an SG Blocks building, and then customized to client specifications.
For more information, please visit www.sgblocks.com.

Join Us On Facebook: https://www.facebook.com/IsodiolInternationalInc/
Twitter: @Isodiolintlinc

ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director

INVESTOR RELATIONS:
Ir@isodiol.com
www.isodiol.com
604-409-4409

Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release.

Click here to connect with Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) for an Investor Presentation.

Source: globenewswire.ca

The Conversation (0)
×